Please read the following information carefully:
Sunovion Pharmaceuticals Inc. reserves the right to limit the number of company-sponsored promotional speaker programs any health care professional (HCP) may attend per calendar year. This policy permits us to make these programs available to a wide audience of HCPs treating patients with COPD while still allowing some flexibility for participants to receive periodic updates when new clinical data is available. This policy also helps HCPs who attend these programs manage the meal expenses that will be reported against them under federal and state aggregate spend reporting.
Sunovion Pharmaceuticals Inc. is committed to the principles in the PhRMA Code on Interactions with Health care Professionals. This code helps to ensure that the highest professional and ethical standards are being met in the pharmaceutical industry. As part of our commitment to the PhRMA code, please note that attendance at this program is limited to health care professionals, and inclusion of spouses or other guests is impermissible.
Please be advised that information such as your name and the value and purpose of any educational item, including meals or other items of value that you receive, will be disclosed in accordance with the federal Sunshine Act. If your employer or the state in which you are licensed or institution with which you are affiliated prohibits receipt from pharmaceutical companies, you MUST identify yourself to the Therapeutic Specialist at such meeting. Thank you for your cooperation.
Attendance is limited to those who have been provided with an invitation that is intended only for the recipient and nontransferable. For your protection, a valid form of identification will be required for admittance to the program.
SUNOVION and are registered trademarks of Sumitomo Dainippon Pharma Co., Ltd. Sunovion Pharmaceuticals Inc. is a U.S. subsidiary of Sumitomo Dainippon Pharma Co., Ltd.
LONHALA and are registered trademarks of Sunovion Pharmaceuticals Inc. MAGNAIR is a registered trademark of PARI Pharma GmbH, used under license.
©2020 Sunovion Pharmaceuticals Inc. All rights reserved. 04/20 LON-US-00046-20